論文 ·日本語 ·未確認
Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy
Yuki Kato ・ Kazuyoshi Shigehara ・ Shohei Kawaguchi ・ Kouji Izumi ・ Yoshifumi Kadono ・ Atsushi Mizokami
- 刊行年
- 2020-02-25
- 収録
- 『The Aging Male』 23(5) pp. 1210-1216
- 出版
- Informa
- 言語
- 英語
- OpenAlex
- W3006874029
- DOI
- 10.1080/13685538.2020.1731450
- PubMed
- 32096413
- MAG
- 3006874029
- ISSN
- 1368-5538
- URL
- https://www.tandfonline.com/doi/pdf/10.1080/13685538.2020.1731450?needAccess=true
要旨
Objective To investigate the time course of total testosterone (TT) recovery after cessation of androgen deprivation therapy (ADT) in Japanese patients treated with brachytherapy.Methods In total, 125 patients with prostate cancer received 6 months of neoadjuvant ADT (nADT) followed by low-dose rate (LDR) brachytherapy. TT was measured every 3 months after cessation of nADT, and some predictive factors affecting TT recovery were analyzed.Results The cumulative incidence rates of TT recovery to normal levels (TT ≥ 3.0 ng/mL) after 12 and 24 months cessation were 49.6% and 81.6%, respectively. The median interval to recover to normal TT was 15 months. In multivariate analysis, the use of a gonadotropin-releasing hormone (GnRH) antagonist as nADT significantly earlier improved to recovery to normal TT level (p = 0.046). Conversely, higher body mass index (BMI) and hypertension significantly prolonged TT recovery to normal (p = 0.026 and p = 0.026, respectively).Conclusions Approximately one-fifth of patients still had low TT levels 2 years after the cessation of 6 months nADT before LDR brachytherapy. Use of a GnRH agonist, higher BMI, and hypertension were the predictive factors for slower TT recovery to normal TT levels after the cessation of nADT.
主題
この書誌の出所
- openalex— W3006874029(2026-08-14取得)
引用
Yuki Kato・Kazuyoshi Shigehara・Shohei Kawaguchi・Kouji Izumi・Yoshifumi Kadono・Atsushi Mizokami(2020-02-25) Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy 『The Aging Male』 23(5) pp. 1210-1216 Informa